Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another installment of The Health Kick Podcast.
In this episode Tim interviews Michael Harsh, non-executive director at Imagion Biosystems (ASX:IBX).
Imagion Biosystems is developing a diagnostic imaging tool called Magsense, which is based on injecting nanoparticles with magnetic fields to detect tumors such as breast cancers.
Listen to the podcast.
Positive Results Received from WSU on MagSense® Dosage – Phase 2 Clinical Trial on HER2 Breast Cancer Imaging Agent
FDA Submission of IND for MagSense® HER2 Phase 2 Clinical Trial on Track Q4 2025 Key Highlights: Wayne State University Collaboration Program Delivers Positive and
